<DOC>
	<DOCNO>NCT02177552</DOCNO>
	<brief_summary>The main purpose study determine effect treatment carboplatin , docetaxel capecitabine patient incurable cancer esophagus stomach .</brief_summary>
	<brief_title>Study Assessing Effects Chemotherapy Advanced Esophagogastric Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Key Patients histologically verify , unresectable metastatic , HER2negative , adenocarcinoma esophagus stomach Men woman less 80 year age Performance status 0 1 Life expectancy &gt; 12 week Adequate organfunction Written inform consent Key Prior chemotherapy adenocarcinoma esophagus stomach chemotherapyfree interval le 6 month Progression firstline chemotherapy unresectable metastatic adenocarcinoma esophagus stomach Chemotherapy epirubicin , oxaliplatin , carboplatin , cisplatin docetaxel le 6 month study entry Prior cumulative dose &gt; 300 mg/m2 epirubicin Grade â‰¥ 2 sideeffects previous chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Esophageal cancer</keyword>
	<keyword>Gastric cancer</keyword>
</DOC>